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Abstract—The in silico prediction of potential drug-target
interactions is of critical importance in drug research. Existing
computational methods have achieved remarkable prediction
accuracy, however usually obtain poor prediction efficiency due
to computational problems. To improve the prediction efficiency,
we propose to predict drug targets based on integration of
heterogeneous features with anchor graph hashing and ensemble
learning. First, we encode each drug as a 5682-bit vector,
and each target as a 4198-bit vector using their heterogeneous
features respectively. Then, these vectors are embedded into low-
dimensional Hamming Space using anchor graph hashing. Next,
we append hashing bits of a target to hashing bits of a drug
as a vector to represent the drug-target pair. Finally, vectors
of positive samples composed of known drug-target pairs and
randomly selected negative samples are used to train and evaluate
the ensemble learning model. The performance of the proposed
method is evaluated on simulative target prediction of 1094 drugs
from DrugBank. Extensive comparison experiments demonstrate
that the proposed method can achieve high prediction efficiency
while preserving satisfactory accuracy. In fact, it is 99.3 times
faster and only 0.001 less in AUC than the best literature method
“Pairwise Kernel Method”.
Index Terms—drug target prediction; heterogeneous features;
anchor graph hashing; ensemble learning.
I. INTRODUCTION
The identification of interactions between drugs and targets
is a key element in drug discovery. It helps to identify new
drugs for known targets or novel targets for existing drugs.
Though various biological assays are available nowadays,
experimental identification of drug-target interaction remains
challenging [1]. To guide and speed up the expensive and
laborious experimental approaches, a variety of in silico pre-
diction methods have been developed [2]. These approaches
can be classified into two types, namely docking simulation
and machine learning. Docking simulation is a powerful
approach, however, it requires 3D structure information of the
target proteins [3]. Moreover, it is time-consuming, in that
a large amount of computational resources are required [4].
Therefore, it’s hard to apply this technique on a large scale.
By comparison, machine learning is more efficient and capable
in large-scale predictions.
Machine learning methods are based on the observation
that similar drugs tend to interact with similar targets [2].
The prediction is performed based on information such as
drug chemical structures [5] [6], drug side-effects [7], target
protein sequences [8], and the known drug-target interactions.
A straightforward approach is to use binary classification
methods where the drug-target pairs are vectorized as input
for binary classifiers, e.g., artificial neural network (ANN)
and support vector machine (SVM) [6] [8] [9] [10]. Another
encouraging approach named bipartite local model (BLM),
is to view drugs and targets as a bipartite graph. BLM
builds one classifier from the drug side and one classifier
from the target side for each drug-target interaction to be
predicted. It can achieve remarkable accuracy, however, leads
to a serious computational problem because a large number
of classifiers have to be trained. The current state-of-the-art
for predicting drug-target interactions using machine learning
is to embed drug similarity measures and target similarity
measures into kernels [6] [8] [11] [12]. By using kernels,
multiple information sources can be integrated to achieve high
prediction accuracy. However, one serious problem is the scale
of the training set with “the number of training drugs times the
number of training targets”, bringing computational difficulties
in large-scale applications.
As described above, existing machine learning methods
either use vectors extracted from drug-target pairs, or the
similarity matrix as input for predictions. The dimension of
the input vectors and the similarity matrix is quite high, which
usually leads to serious computational problems. To tackle
this problem, we introduce anchor graph hashing (AGH), an
excellent hashing method in both the speed and accuracy
[13]. It can embed the data into Hamming space so that the
neighbors in the original data space remain neighbors in the
Hamming space [14]. Therefore, AGH is an ideal technique
for dimension reduction. Recently, ensemble learning has been
widely used in bioinformatics [15]. It combines multiple hy-
potheses of the base learners to form a better hypothesis, thus
producing better predictive performance. Lots of application
have proved the success of ensemble learning [16] [17] [18].
In this work, we propose to predict drug-target interactions
from heterogeneous spaces with anchor graph hashing and
ensemble learning (AGHEL). First, every drug is encoded
as a vector using its heterogeneous features including drug
chemical structures, drug side-effects, and drug substituents.
Analogously, each target is encoded as a vector using its
related Gene Ontology (GO). Next, the high-dimensional drug
and target vectors are compressed into short vectors (i.e.,
hashing bits) in Hamming space using AGH. Then we can
get the compressed vector of arbitrary drug-target pair by
appending the compressed target vector to the compressed
drug vector. Finally, compressed vectors of drug-target pairs
are used as input to train and evaluate the ensemble learning
model. We employ random forest [19] and XGBoost [20] as
base learners of the ensemble learning model. Our innovation
lies in integrating heterogeneous drug and target features into
a unified framework for predictions, in utilizing the advanced
anchor graph hashing to reduce vector dimension, and in the
employment of ensemble learning to improve the prediction
performance.
II. RELATED WORK
A plenty of prediction models have been developed to
predict drug-target interactions. We discuss three typical mod-
els which we use as comparison methods, namely nearest
neighbor (NN) algorithm, pairwise kernel method (PKM), and
bipartite local models (BLM).
A. Nearest Neighbor
NN is usually used as the baseline method [8]. Given a
test candidate drug, NN predicts it to interact with targets
known to interact with its nearest drug. Likewise, NN predicts
a test candidate target to interact with drugs known to interact
with its nearest target. Then each interaction has two predic-
tion results/scores which will be further combined to give a
definitive prediction. NN is simple and efficient, however, the
performance is relatively low.
B. Pairwise Kernel Method
PKM is a typical kernel based method, which uses drug-
target interactions as instances [4]. Given two drug pairs
(d, t) and (d′, t′), PKM first computes the similarity between
them by multiplying the drug similarity score and the target
similarity score as follows:
s((d, t), (d′, t′)) = sd(d, d′) ∗ st(t, t′) (1)
where s, sd, and st are similarity functions of interactions,
drugs and targets respectively, d and d′ are drugs, and t and
t′ are targets. Then it uses the calculated similarity matrix of
drug-target pairs as the self-defined kernel to train an SVM
classifier. Finally, the trained SVM predicts scores for test
drug-target pairs. By using kernels, PKM can integrate multi-
ple information sources and achieve high prediction accuracy.
However, it leads to computational difficulties in large-scale
problems due to the scale of training set. For instance, for the
1094 drugs and 1556 targets used in this work, the size of
the kernel matrix will be (1094*1556)*(1094*1556) which is
quite large.
C. Bipartite Local Models
BLM views drug-target interactions as a bipartite network,
in which vertexes are drugs and targets, edges are their
interactions. Each drug-target interaction is predicted from the
drug side and target side respectively using a local model
(classifier). We take the prediction of a drug-target pair (d, t)
as an example to illustrate the process. BLM first checks
whether every target in the traning set known to interact
with drug d, and assign a label “1” if so; otherwise “0”;
Next, vectors of all training targets or their similarity matrix
together with their labels are used to train a local model. Then
the trained local model predicts the label of t. Analogously,
BLM trains a local model using drugs in the training set
and obtain the label of d. Finally, two prediction scores of
d and t are combined to give a final prediction. BLM builds
one classifier from the drug side and one classifier from the
target side for each drug-target pair. It can achieve remarkable
accuracy. However, BLM leads to a serious computational
problem because a large number of classifiers (i.e., twice of
interactions to be predicted) have to be trained.
III. DRUG TARGET PREDICTION WITH ANCHOR GRAPH
HASHING AND ENSEMBLE LEARNING
To tackle the computational problem of large-scale drug
target predictions while keeping the prediction accuracy, we
introduce two advanced techniques namely anchor graph
hashing and ensemble learning for predictions. Anchor graph
hashing is capable to embed high-dimensional data into low-
dimensional Hamming space while keeping neighbors in the
original data space remaining neighbors in Hamming space.
That’s why we employ it to reduce the dimension of raw drug
vectors and target vectors. Ensemble learning has shown its
advantages in many applications of bioinformatics. We make
full use of its advantage to better capture the data features and
obtain better performance.
A. Prediction Framework
The framework of our method is illustrated in Figure 1.
First, each drug is encoded as a 5682-bit vector using its chem-
ical substructures (881), side-effects (4063), and substituents
(738) where each bit represents the presence or absence of
the feature by 1 or 0. Likewise, every target is encoded as
a vector of 4,198 bits using the Gene Ontology. Then, we
employ AGH to embed raw drug and target vectors into low-
dimensional Hamming Space (12/16/24/32/48/64 bits). After
that, we use all known drug-target interactions as positive
samples, and randomly select the same number of negative
samples from unknown interactions. Next, sample vectors
formed by appending corresponding target hashing bits to the
drug hashing bits are used as input to train and evaluate the
ensemble learning model. The ensemble learning model em-
ploys random forest and XGBoost as base learners, and gives
the final prediction scores by averaging the scores predicted
by them. Finally, the prediction results are evaluated through
10-fold cross-validation on both the prediction accuracy and
prediction efficiency.
Fig. 1. The framework for drug target prediction by anchor graph hashing and ensemble learning.
B. Data Representation
We collected 1094 drugs and 1556 targets for experiments.
Each drug was represented by a 5682 dimensional binary
vector using its chemical structure (881), associated side-
effects (4063), and substituents (738). The drug chemical
structure is represented by 881 chemical substructures defined
in PubMed [21]. We obtained 4063 associated side-effects
from SIDER [22] and 738 substituents from DrugBank [23].
The elements of the drug vector encode for the presence or ab-
sence of each of the features (i.e., chemical substructures/side-
effects/substituents) by 1 or 0. We obtained 4198 unique GO
terms which are associated with the targets from the EMBL-
EBI website [24]. Analogously, we represented each target as
a 4198 dimensional binary vector where each element encodes
the presence or absence of each of the GO terms by 1 or 0.
C. Anchor Graph Hashing
The goal of AGH is to learn short binary codes such
that neighbors in the input space are mapped to neighbors
in the Hamming space [14]. AGH seeks an r-bit Hamming
embedding Y ∈ {1, -1}n×rfor n points in the input space by
minimizing
min
Y
1
2
n∑
i,j=1
‖Yi − Yj‖2Aij = tr(Y >LY )
s.t Y ∈ {1, -1}n×r, 1>Y = 0, Y >Y = nIr×r
(2)
where Yj is the jth row of Y representing the r-bit code
for point xj , and Aij is the similarity between the data pair
(xi, xj). To solve the above NP-hard problem, AGH uses
a small subset of m points called anchors to approximate
the data neighborhood structure [25]. Specifically, K-means
is performed on all n points to get m (m<<n) cluster centers
(anchors) U = {uj ∈ Rd}mj=1 first. Next AGH computes
truncated similarity matrix between all n data points and m
anchors as follows:
Zij =

exp(−D2(xi,uj)/t)∑
j
′∈〈i〉 exp(−D2(xi,uj′ )/t)
,∀j ∈ 〈i〉
0 otherwise
(3)
where 〈i〉 ∈ [1 : m] denotes the indices of s (s<<m) nearest
anchors of point xi in U according to a distance function
D(), and t is the bandwidth parameter. Then the adjacent
matrix A can be approximated as A
′
= ZV −1Z> where
V = diag(Z>1) ∈ Rm×m [25]. The eigenvectors of A′ can
be calculated easily by using its low-rank property. In partic-
ular, AGH solves the eigenvalue system of a small m×m
matrix M = V −1/2Z>ZV −1/2. This produces r eigenvector-
eigenvalue pairs {(pk, σk)}rk=1 where 0 < σr ≤ ... ≤ σ1 < 1.
Finally, AGH obtains the desired spectral embedding matrix
as
Y =
√
nZV −1/2P
∑−1/2
(4)
where P = [p1, ..., pr] ∈ Rm×r and
∑
= diag(σ1, ..., σr) ∈
Rr×r.
Using AGH, the high-dimension input vectors are com-
pressed into low-dimension hashing bits where neighbours in
the input space remain neighbours in the output space.
D. Sample Selection
All known drug-target pairs were used as positive samples
and assigned the label “1”. An equal number of negative
samples were randomly selected from unknown drug-target
pairs and assigned the label “0”. To avoid bias, the negative
sample selection process were repeated 5 times and the average
results were used for evaluation. After we obtained positive
samples and negative samples, we represented them as vectors
by appending corresponding target hashing bits to the drug
hashing bits. Then these vectors were used as input of the
ensemble learning model.
E. Ensemble Learning
We chose random forest and XGBoost as the base learners
of the ensemble learning model as they perform well on low-
dimension data. We simply took the average value of their
prediction scores as the final prediction score.
F. 10-fold Cross-validation
The performance is evaluated by 10-fold cross validation:
(1) samples in the gold standard are split into 10 roughly
equal-sized subsets; (2) each subset is taken in turn as the
test set, and the remaining subsets are used as training set; (3)
all results over the 10-fold validation are used for evaluation.
We randomly chose the same number of negative samples
as that of positive samples (known drug-target interactions).
To avoid bias, we repeated the sample selection process
and cross-validation 5 times respectively, which means each
method would run 25 (5*5) times and the average results were
used for final evaluation. We employed the receiver operating
characteristic curve (ROC), the area under ROC curve (AUC)
and, the execution time as the evaluation metrics to evaluate
the prediction performance.
IV. RESULTS
A. Data Resources
Since drug-target interactions are continually being iden-
tified with time. Instead of using old data from existing
literature, we collected the dataset from well-known databases
by ourselves. Specifically, the drugs were collected from Drug-
Bank [23], a comprehensive drug database. The targets were
obtained from DrugBank and DrugCentral [26]. Table I and
Figure 2 show the details of our dataset (Dataset AGHEL).
By comparison, we also list the datasets used in PKM
(Dataset PKM) and BLM (Dataset BLM). From table I, we
can see that our dataset has much more targets and know
interactions.
Fig. 2. Characteristics of targets and their associated drugs. The left panel
is the histogram of the associated drug number for the targets and the right
panel is the index-plot of the number of associated drugs for each target.
TABLE I
DATASET USED IN THIS WORK AND TWO DATASETS USED IN
PUBLICATIONS.
Dataset Numberof drugs
Number
of targets
Number of
interactions
Dataset AGHEL 1094 1556 11,819
Dataset BLM 932 989 5127
Dataset PKM 1205 889 2782
B. Parameter Optimization
The key parameters of anchor graph hashing are the number
of its layer and the output hashing bits [14]. Therefore,
we performed experiments to find out the best settings for
the hashing layer and output hashing bit. Specifically, we
employed K-means to cluster all raw drug (target) vectors
to get 100 cluster centers as their anchors first. Then we
obtained r-bit (r ∈ {12, 16, 24, 32, 48, 64}) hashing bits for
drugs(targets) with their anchors and AGH of different number
of layers. Finally, the drug hashing bits and the target hashing
bits obtained from the same number of layers and bits are
combined as vectors for predictions and evaluations. The
experiment results are illustrated in Figure 3. It can be seen
obviously that the AUC increases with the number of hashing
bits for both 1-layer AGH and 2-layer AGH. Besides, 1-layer
AGH outperforms 2-layer AGH on the same number of bits.
Based on the above observation, we set the layer of AGH as
1 and the number of output hashing bits as 64 for AGHEL in
the following experiment.
C. Comparison Results
To demonstrate the advantage of our method, we compared
AGHEL with three different types of existing prediction meth-
ods on both the prediction accuracy and prediction efficiency.
Details of the three comparison methods namely NN, PKM,
and BLM, are detailedly introduced in the “Related Work”
section. All methods were performed on a Linux workstation
with dual Intel XEON 3.4GHz processors (14 cores) and 256
GB of main memory.
Figure 4 shows the average execution time of the four
methods. We can see that AGHEL is the fastest, completed
predictions of 23,638 drug-target interactions in 9.99 s (0.53s
for hashing compression and 9.46s for predictions). It is 4.62
Fig. 3. The AUC (ROC score) of AGHEL with different AGH settings. The
x-axis is the number of output hashing bits and the y-axis is the AUC score.
Fig. 4. The average execution time (s) of four methods using 10-fold cross-
validation.
times faster than the second fastest method NN, and 5181.44
times faster than the slowest method BLM. Among the three
existing comparison methods, NN is the fastest, benefits from
its simple prediction principle i.e., predicting the interacted
targets (drugs) for drugs(targets) the same as its nearest drug
(target). BLM is the slowest because two classifiers need to be
trained for each interactions. It means 47,276 classifiers have
to be trained for predicting the whole 23,638 interactions. By
comparison, PKM is more efficient than BLM, as only one
classifier needs to be trained. However due to the large size of
the kernel matrix (23, 638 × 23, 638), it is still much slower
than NN and AGHEL. AGHEL trains one classifier for all pre-
dictions as well. However, compared with PKM whose input
vector dimension equals to 23,638, the input vector dimension
of AGHEL is largely reduced from 9,880 (5,682+4,198) to 128
(64+64) by its AGH component. Through this fast process
(0.53s), the prediction time of AGHEL decreases largely. This
explains why AGHEL costs the least execution time.
Fig. 5. The ROC curve of four methods from 10-fold cross-validation
experiments.
To draw the ROC curves, we merged all prediction scores
from the 25 repeated experiments for each method and a
single ROC curve was drawn. Figure 5 illustrates the obtained
ROC curves. From it, we can see that PKM (colored blue)
achieves the best performance. It has been demonstrated to be
the most powerful method in one review of machine learning
methods for drug target predictions [4]. The proposed method
(colored red) AGHEL achieves the second best performance.
To better visualize the differences between the four methods,
we computed the average AUC for each method by averaging
AUCs from its 25 repeated experiments. The average AUCs
are shown in Figure 6. It can be seen that AGHEL (0.893)
achieves satisfactory AUC, only 0.001 less than PKM (0.894).
Following AGHEL are BLM (0.879) and NN (0.836).
Fig. 6. The AUC of four methods from 10-fold cross-validation experiments.
V. CONCLUSION
In this work, we propose to predict drug targets based on
integration of heterogeneous features with anchor graph hash-
ing and ensemble learning. The contribution of the proposed
method lies in the integration of drug chemical structures,
drug side-effects, drug substituents and GO terms of targets
in a unified framework for predictions, in the novel use of
anchor graph hashing, and in the implement of ensemble
learning. To our knowledge, no existing work gathers the
above features in the field of drug target prediction. From
the experimental results, it has been demonstrated that the
proposed method, namely AGHEL achieves satisfactory per-
formance on both the execution time and prediction accuracy.
Compared with three state-of-the-art methods, it is the fastest
and the second most accurate. Owing to the introduction of
anchor graph hashing, the prediction process is sharply sped
up by decreasing dimensions of input vectors. With the help
of integration of heterogeneous features of drugs and targets,
and the employment of ensemble learning, AGHEL achieves
high prediction accuracy.
The proposed method is of value to the drug discovery
process, which aims to identify novel targets for existing drugs
or new drugs for known targets. It can guide and speed up the
laborious, expensive and tedious experimental identification
of drug-target interaction [1]. In this work, drug chemical
structures, drug side-effects, drug substituents and GO terms
of targets are integrated to predict drug targets. It should be
pointed out that more drug and target information, such as
drug indications and target sequences, can be integrated. The
limitation of the proposed method is its dependence on the
used drug and target features which are not always available
and complete for all drugs. Therefore, to develop methods
which are able to predict drug targets efficiently and accurately
with easy accessible data will be our future work.
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